Comparative Pharmacology
Head-to-head clinical analysis: LOPRESSOR versus METOPROLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPRESSOR versus METOPROLOL.
LOPRESSOR vs Metoprolol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors, predominantly in cardiac tissue.
Selective beta-1 adrenergic receptor antagonist; competitively blocks beta-1 receptors in the heart, decreasing heart rate, contractility, and cardiac output; reduces renin release from kidneys.
50 mg orally twice daily, titrate up to 100 mg twice daily as needed.
Metoprolol tartrate: Initial 50 mg PO BID or 100 mg PO daily; maintenance 100-450 mg/day in divided doses. Metoprolol succinate (extended-release): Initial 25-100 mg PO once daily; maintenance 100-400 mg once daily.
None Documented
None Documented
Clinical Note
moderateMetoprolol + Digoxin
"Metoprolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateMetoprolol + Digitoxin
"Metoprolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateMetoprolol + Deslanoside
"Metoprolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateMetoprolol + Acetyldigitoxin
"Metoprolol may increase the bradycardic activities of Acetyldigitoxin."
Terminal elimination half-life: 3-7 hours (mean 4.5 h); may be prolonged in hepatic impairment or elderly
3–7 hours for metoprolol; prolonged in poor CYP2D6 metabolizers (up to 8–16 hours). Clinical context: dosing interval typically twice daily (immediate-release) or once daily (extended-release).
Renal: ~95% (primarily as metabolites, <5% unchanged); fecal: ~5%
Primarily hepatic metabolism (CYP2D6) producing inactive metabolites; renal excretion accounts for <5% unchanged. Fecal elimination minimal.
Category C
Category C
Beta-Blocker
Beta-Blocker